{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:26:04Z","timestamp":1786465564076,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cardiovasc Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Coronary artery disease often develops silently before myocardial infarction, and current risk-based prevention pathways miss some individuals with clinically important disease, particularly those without standard modifiable cardiovascular risk factors. High-sensitivity cardiac troponin I is a blood biomarker of low-level myocardial injury, but its relationship to silent coronary atherosclerosis remains incompletely understood. Here we show, in 1,613 adults undergoing coronary computed tomography (CT) imaging, that low-level high-sensitivity cardiac troponin I is associated with clinically actionable coronary disease, defined by coronary calcium score \u2265100, and with quantitative CT markers of plaque burden. A threshold of 2.3\u2009ng\u2009l\n                    <jats:sup>\u22121<\/jats:sup>\n                    enriched for actionable disease, especially in individuals without standard risk factors. Normalizing troponin for myocardial mass, age and renal function improved prediction and provided mechanistic insight into baseline troponin elevation in chronic coronary syndromes. A two-stage strategy using troponin before CT imaging increased diagnostic yield and reduced the number of scans required. Prospective validation is warranted before clinical implementation.\n                  <\/jats:p>","DOI":"10.1038\/s44161-026-00837-z","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:08:40Z","timestamp":1785402520000},"page":"763-776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utility of high-sensitivity cardiac troponin I normalized to left ventricular mass in detection of stable coronary artery disease"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8132-4047","authenticated-orcid":false,"given":"Sina","family":"Fathieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1154-3011","authenticated-orcid":false,"given":"Michael P.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine A.","family":"Bate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Vernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah","family":"Genetzakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soloman","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Murtagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-2603","authenticated-orcid":false,"given":"Jean Y.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bonnitcha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Celermajer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6611-8229","authenticated-orcid":false,"given":"Louise","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinay","family":"Bhindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamil","family":"Mayet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart M.","family":"Grieve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5080-6083","authenticated-orcid":false,"given":"Gemma A.","family":"Figtree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"837_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013296","volume":"8","author":"ST Vernon","year":"2019","unstructured":"Vernon, S. T. et al. ST-segment-elevation myocardial infarction (STEMI) patients without standard modifiable cardiovascular risk factors\u2014how common are they, and what are their outcomes? J. Am. Heart Assoc. 8, e013296 (2019).","journal-title":"J. Am. Heart Assoc."},{"key":"837_CR2","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1177\/2047487317720287","volume":"24","author":"ST Vernon","year":"2017","unstructured":"Vernon, S. T. et al. Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. Eur. J. Preven. Cardiol. 24, 1824\u20131830 (2017).","journal-title":"Eur. J. Preven. Cardiol."},{"key":"837_CR3","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(21)00272-5","volume":"397","author":"GA Figtree","year":"2021","unstructured":"Figtree, G. A. et al. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet 397, 1085\u20131094 (2021).","journal-title":"Lancet"},{"key":"837_CR4","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1093\/cvr\/cvab145","volume":"117","author":"GA Figtree","year":"2021","unstructured":"Figtree, G. A. & Vernon, S. T. Coronary artery disease patients without standard modifiable risk factors (SMuRFs) \u2014 a forgotten group calling out for new discoveries. Cardiovasc. Res. 117, e76\u2013e78 (2021).","journal-title":"Cardiovasc. Res."},{"key":"837_CR5","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.jacc.2019.08.012","volume":"74","author":"A Ahmadi","year":"2019","unstructured":"Ahmadi, A., Argulian, E., Leipsic, J., Newby, D. E. & Narula, J. From subclinical atherosclerosis to plaque progression and acute coronary events. J. Am. Coll. Cardiol. 74, 1608\u20131617 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"837_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/MED.0000000000000317","volume":"24","author":"Y Kataoka","year":"2017","unstructured":"Kataoka, Y., Andrews, J., Puri, R., Psaltis, P. J. & Nicholls, S. J. Plaque burden, microstructures and compositions underachieving very low LDL-C levels. Curr. Opin. Endocrinol. Diabetes Obes. 24, 122\u2013132 (2017).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"837_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2023.01.017","volume":"367","author":"G Di Giovanni","year":"2023","unstructured":"Di Giovanni, G., Kataoka, Y., Bubb, K., Nelson, A. J. & Nicholls, S. J. Impact of lipid lowering on coronary atherosclerosis moving from the lumen to the artery wall. Atherosclerosis 367, 8\u201314 (2023).","journal-title":"Atherosclerosis"},{"key":"837_CR8","doi-asserted-by":"publisher","first-page":"C106","DOI":"10.1093\/eurheartjsupp\/suad013","volume":"25","author":"G Zanda","year":"2023","unstructured":"Zanda, G. & Varbella, F. Stabilization of vulnerable plaque in the ACS patient: evidence from HUYGENS studies. Eur. Heart J. Suppl. 25, C106\u2013C108 (2023).","journal-title":"Eur. Heart J. Suppl."},{"key":"837_CR9","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1001\/jama.2018.2525","volume":"319","author":"EP Navarese","year":"2018","unstructured":"Navarese, E. P. et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 319, 1566\u20131579 (2018).","journal-title":"JAMA"},{"key":"837_CR10","doi-asserted-by":"crossref","unstructured":"Figtree, G. A. A Quest for Zero Heart Attacks. Scientia https:\/\/www.scientia.global\/professor-gemma-figtree-a-quest-for-zero-heart-attacks\/ (2023).","DOI":"10.33548\/SCIENTIA915"},{"key":"837_CR11","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1161\/CIRCULATIONAHA.121.055340","volume":"144","author":"G Bergstr\u00f6m","year":"2021","unstructured":"Bergstr\u00f6m, G. et al. Prevalence of subclinical coronary artery atherosclerosis in the general population. Circulation 144, 916\u2013929 (2021).","journal-title":"Circulation"},{"key":"837_CR12","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/S0140-6736(25)00055-8","volume":"405","author":"S Zaman","year":"2025","unstructured":"Zaman, S. et al. The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma. Lancet 405, 1264\u20131312 (2025).","journal-title":"Lancet"},{"key":"837_CR13","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1161\/CIRCULATIONAHA.118.038529","volume":"139","author":"P Welsh","year":"2019","unstructured":"Welsh, P. et al. Cardiac troponin T and troponin I in the general population. Circulation 139, 2754\u20132764 (2019).","journal-title":"Circulation"},{"key":"837_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1161\/ATVBAHA.115.306818","volume":"36","author":"C Caselli","year":"2016","unstructured":"Caselli, C. et al. Effect of coronary atherosclerosis and myocardial ischemia on plasma levels of high-sensitivity troponin T and NT-proBNP in patients with stable angina. Arter. Thromb. Vasc. Biol. 36, 757\u2013764 (2016).","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"837_CR15","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s11255-012-0128-x","volume":"44","author":"MR Gaiki","year":"2012","unstructured":"Gaiki, M. R., DeVita, M. V., Michelis, M. F., Panagopoulos, G. & Rosenstock, J. L. Troponin I as a prognostic marker of cardiac events in asymptomatic hemodialysis patients using a sensitive troponin I assay. Int. Urol. Nephrol. 44, 1841\u20131845 (2012).","journal-title":"Int. Urol. Nephrol."},{"key":"837_CR16","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.jacc.2025.02.016","volume":"85","author":"ASV Shah","year":"2025","unstructured":"Shah, A. S. V. et al. Cardiac troponins and cardiovascular disease risk prediction. J. Am. Coll. Cardiol. 85, 1471\u20131484 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"837_CR17","unstructured":"Global Heart Hub. Achieving Early Detection and Diagnosis of Cardiovascular Disease: A Manifesto for Change (Global Heart Hub, 2025)."},{"key":"837_CR18","doi-asserted-by":"publisher","unstructured":"Fathieh, S. et al. Evaluating the role of lipoprotein(a) in enhancing risk stratification for the presence and extent of subclinical coronary artery disease burden: a BioHEART-CT study. Eur. J. Prevent. Cardiol. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf323 (2025).","DOI":"10.1093\/eurjpc\/zwaf323"},{"key":"837_CR19","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.jacc.2023.06.045","volume":"82","author":"GA Figtree","year":"2023","unstructured":"Figtree, G. A. et al. Clinical pathway for coronary atherosclerosis in patients without conventional modifiable risk factors: JACC state-of-the-art review. J. Am. Coll. Cardiol. 82, 1343\u20131359 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"837_CR20","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.hlc.2021.04.026","volume":"30","author":"D Playford","year":"2021","unstructured":"Playford, D., Hamilton-Craig, C., Dwivedi, G. & Figtree, G. Examining the potential for coronary artery calcium (CAC) scoring for individuals at low cardiovascular risk. Heart Lung Circ. 30, 1819\u20131828 (2021).","journal-title":"Heart Lung Circ."},{"key":"837_CR21","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints, C. et al. 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 45, 3415\u20133537 (2024).","journal-title":"Eur. Heart J."},{"key":"837_CR22","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","volume":"15","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls, S. J. et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc. Imaging 15, 1308\u20131321 (2022).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"837_CR23","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.jacc.2010.02.026","volume":"55","author":"SJ Nicholls","year":"2010","unstructured":"Nicholls, S. J. et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J. Am. Coll. Cardiol. 55, 2399\u20132407 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"837_CR24","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","volume":"375","author":"M Jun","year":"2010","unstructured":"Jun, M. et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375, 1875\u20131884 (2010).","journal-title":"Lancet"},{"key":"837_CR25","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent, C. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670\u20131681 (2010).","journal-title":"Lancet"},{"key":"837_CR26","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1161\/CIRCHEARTFAILURE.111.965327","volume":"5","author":"WJ Kop","year":"2012","unstructured":"Kop, W. J. et al. Cardiac microinjury measured by troponin T predicts collagen metabolism in adults aged \u226565 years with heart failure. Circ. Heart Fail. 5, 406\u2013413 (2012).","journal-title":"Circ. Heart Fail."},{"key":"837_CR27","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jcmg.2018.01.021","volume":"12","author":"JL Januzzi","year":"2019","unstructured":"Januzzi, J. L. et al. High-sensitivity troponin I and coronary computed tomography in symptomatic outpatients with suspected CAD: insights from the PROMISE trial. JACC Cardiovasc. Imaging 12, 1047\u20131055 (2019).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"837_CR28","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0735-1097(02)02608-6","volume":"40","author":"BJ Freda","year":"2002","unstructured":"Freda, B. J., Tang, W. W., Van Lente, F., Peacock, W. F. & Francis, G. S. Cardiac troponins in renal insufficiency: review and clinical implications. J. Am. Coll. Cardiol. 40, 2065\u20132071 (2002).","journal-title":"J. Am. Coll. Cardiol."},{"key":"837_CR29","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1373\/clinchem.2017.277186","volume":"64","author":"AHB Wu","year":"2018","unstructured":"Wu, A. H. B. et al. Clinical laboratory practice recommendations for the use of cardiac troponin in acute coronary syndrome: expert opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. Clin. Chem. 64, 645\u2013655 (2018).","journal-title":"Clin. Chem."},{"key":"837_CR30","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","volume":"138","author":"K Thygesen","year":"2018","unstructured":"Thygesen, K. et al. Fourth universal definition of myocardial infarction (2018). Circulation 138, e618\u2013e651 (2018).","journal-title":"Circulation"},{"key":"837_CR31","first-page":"665","volume":"104","author":"EW Carlton","year":"2018","unstructured":"Carlton, E. W. et al. Assessment of the 2016 National Institute for Health and Care Excellence high-sensitivity troponin rule-out strategy. Heart 104, 665\u2013672 (2018).","journal-title":"Heart"},{"key":"837_CR32","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1373\/clinchem.2016.262659","volume":"63","author":"JT Neumann","year":"2017","unstructured":"Neumann, J. T. et al. Immediate rule-out of acute myocardial infarction using electrocardiogram and baseline high-sensitivity troponin I. Clin. Chem. 63, 394\u2013402 (2017).","journal-title":"Clin. Chem."},{"key":"837_CR33","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1093\/eurheartj\/ehy217","volume":"39","author":"MJ Budoff","year":"2018","unstructured":"Budoff, M. J. et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). Eur. Heart J. 39, 2401\u20132408 (2018).","journal-title":"Eur. Heart J."},{"key":"837_CR34","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren, F. L. J. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 42, 3227\u20133337 (2021).","journal-title":"Eur. Heart J."},{"key":"837_CR35","doi-asserted-by":"publisher","first-page":"e1154","DOI":"10.1161\/CIR.0000000000001457","volume":"153","author":"RS Blumenthal","year":"2026","unstructured":"Blumenthal, R. S. et al. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 153, e1154\u2013e1276 (2026).","journal-title":"Circulation"},{"key":"837_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ahj.2023.06.009","volume":"264","author":"MP Gray","year":"2023","unstructured":"Gray, M. P. et al. Incorporating a polygenic risk score-triaged coronary calcium score into cardiovascular disease examinations to identify subclinical coronary artery disease (ESCALATE): protocol for a prospective, nonrandomized implementation trial. Am. Heart J. 264, 163\u2013173 (2023).","journal-title":"Am. Heart J."},{"key":"837_CR37","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/jalm\/jfab017","volume":"6","author":"S Masotti","year":"2021","unstructured":"Masotti, S. et al. Evaluation and comparison with other high-sensitivity methods of analytical performance and measured values of a new laboratory test for cardiac troponin I assay. J. Appl. Lab. Med. 6, 1237\u20131250 (2021).","journal-title":"J. Appl. Lab. Med."},{"key":"837_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22311","volume":"32","author":"J Wang","year":"2018","unstructured":"Wang, J. et al. Evaluation of a newly developed chemiluminescence immunoassay for detecting cardiac troponin T. J. Clin. Lab. Anal. 32, e22311 (2018).","journal-title":"J. Clin. Lab. Anal."},{"key":"837_CR39","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/clinchem\/hvad185","volume":"70","author":"KM Aakre","year":"2023","unstructured":"Aakre, K. M., Apple, F. S., Mills, N. L., Meex, S. J. R. & Collinson, P. O. Biomarkers tIFoCCCoCAoC. Lower limits for reporting high-sensitivity cardiac troponin assays and impact of analytical performance on patient misclassification. Clin. Chem. 70, 497\u2013505 (2023).","journal-title":"Clin. Chem."},{"key":"837_CR40","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.hlc.2024.03.007","volume":"33","author":"H Kempton","year":"2024","unstructured":"Kempton, H., Jones, G., McCready, M. & Kovacic, J. Macrotroponin in the COVID-19 era: an under-recognised cause of persistent troponin elevation. Heart Lung Circ. 33, 1147\u20131150 (2024).","journal-title":"Heart Lung Circ."},{"key":"837_CR41","doi-asserted-by":"publisher","first-page":"e028649","DOI":"10.1136\/bmjopen-2018-028649","volume":"9","author":"KA Kott","year":"2019","unstructured":"Kott, K. A. et al. Biobanking for discovery of novel cardiovascular biomarkers using imaging-quantified disease burden: protocol for the longitudinal, prospective, BioHEART-CT cohort study. BMJ Open 9, e028649 (2019).","journal-title":"BMJ Open"},{"key":"837_CR42","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jcct.2016.10.002","volume":"10","author":"S Abbara","year":"2016","unstructured":"Abbara, S. et al. SCCT guidelines for the performance and acquisition of coronary computed tomographic angiography: A report of the Society of Cardiovascular Computed Tomography Guidelines Committee: endorsed by the North American Society for Cardiovascular Imaging (NASCI). J. Cardiovasc. Comput. Tomogr. 10, 435\u2013449 (2016).","journal-title":"J. Cardiovasc. Comput. Tomogr."},{"key":"837_CR43","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0735-1097(90)90282-T","volume":"15","author":"AS Agatston","year":"1990","unstructured":"Agatston, A. S. et al. Quantification of coronary artery calcium using ultrafast computed tomography. J. Am. Coll. Cardiol. 15, 827\u2013832 (1990).","journal-title":"J. Am. Coll. Cardiol."},{"key":"837_CR44","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.hlc.2020.09.943","volume":"30","author":"GF Watts","year":"2021","unstructured":"Watts, G. F. et al. Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia. Heart Lung Circ. 30, 324\u2013349 (2021).","journal-title":"Heart Lung Circ."},{"key":"837_CR45","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0002-9149(83)80105-2","volume":"51","author":"GG Gensini","year":"1983","unstructured":"Gensini, G. G. A more meaningful scoring system for determining the severity of coronary heart disease. Am. J. Cardiol. 51, 606 (1983).","journal-title":"Am. J. Cardiol."},{"key":"837_CR46","doi-asserted-by":"publisher","first-page":"e230024","DOI":"10.1148\/ryai.230024","volume":"5","author":"J Wasserthal","year":"2023","unstructured":"Wasserthal, J. et al. TotalSegmentator: robust segmentation of 104 anatomical structures in CT images. Radiol. Artif. Intell. 5, e230024 (2023).","journal-title":"Radiol. Artif. Intell."},{"key":"837_CR47","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41592-020-01008-z","volume":"18","author":"F Isensee","year":"2021","unstructured":"Isensee, F., Jaeger, P. F., Kohl, S. A. A., Petersen, J. & Maier-Hein, K. H. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat. Methods 18, 203\u2013211 (2021).","journal-title":"Nat. Methods"},{"key":"837_CR48","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","volume":"30","author":"A Fedorov","year":"2012","unstructured":"Fedorov, A. et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn. Reson. Imaging 30, 1323\u20131341 (2012).","journal-title":"Magn. Reson. Imaging"}],"container-title":["Nature Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00837-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00837-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00837-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:02:56Z","timestamp":1786460576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00837-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["837"],"URL":"https:\/\/doi.org\/10.1038\/s44161-026-00837-z","relation":{},"ISSN":["2731-0590"],"issn-type":[{"value":"2731-0590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.F. is funded by a BHF Healthcare Innovation Fund Grant (HI\/B4\/25\/360206). G.A.F. reports grant funding from National Health and Medical Research Council (NHMRC, Investigator Grant), NSW Health (NSW Cardiovascular Research Capacity Program, Senior Researcher), North Foundation, Australian Cardiovascular Alliance, Abbott Diagnostic, Roche Diagnostics International Ltd and Novartis Foundation; payments or honoraria from Abbott, Boehringer-Ingelheim, CPC Clinical Research, CSL, GSK, Heart Foundation, National Heart Centre Singapore and Sanofi; travel support from Amgen, Novo Nordisk and World Heart Foundation; patents planned, issued or pending of \u2018Patent Biomarkers and Oxidative Stress\u2019 awarded USA May 2017 (US9638699B2) issued to Northern Sydney Local Health District, \u2018Methods for predicting coronary artery disease\u2019 AU202290266 issued to The University of Sydney, and \u2018Methods for treatment and prevention of vascular disease\u2019 PCT\/AU2015\/000548 issued to The University of Sydney\/Northern Sydney Local Health District; leadership or fiduciary role for CAD Frontiers Pty Ltd, Prokardia Pty Ltd and Kardiomics Pty Ltd; G.A.F. serves as CMO for the nonprofit, CAD Frontiers, with industry partners including, Novartis, Amgen, AstraZeneca, Siemens Healthineers, ELUCID, Foresite Labs LLC, HeartFlow, Canon, Cleerly, Caristo, Genetech, Artyra, and Bitterroot Bio and Allelica; G.A.F. serves Board Director for the Australian Cardiovascular Alliance (past President), currently serves as Executive Committee Member for CPC Clinical Research, Founding Director and CMO for Prokardia and Kardiomics, and Executive Committee member for the CAD Frontiers A2D2 Consortium. S.V. reports grant support by a post-doctoral fellowship (#106742-2022_PDF) from the National Heart Foundation of Australia; honoraria from Amgen and Novartis Pharmaceuticals Australia; and travel support from Amgen. S.M.G. acknowledges the support of the Parker-Hughes Bequest, the New South Wales Office of Health and Medical Research and the Frecker Family. G.M. is a full-time employee and shareholder of Abbott Laboratories. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}